A new licensing agreement between BioSig Technologies and Mayo Clinic will seek to significantly advance current arrhythmia treatments.BioSig Technologies Inc.
BioSig Technologies and Mayo Clinic have joined forces once again, this time to develop a new product pipeline to support some of the more advanced features of BioSig's Pure EP System.
Samuel Asirvatham, MD, Mayo Clinic's vice-chair of innovation and medical director of the electrophysiology (EP) laboratory, will lead the new development program. The company previously signed a 10-year collaboration agreement with Mayo Clinic in March 2017.
"The new product that we intend to develop under the latest licensing will seek to significantly advance the current arrhythmia treatments," said Kenneth Londoner, BioSig's CEO and chairman. "It will be an exciting journey, and we look forward to reporting on our progress.”
BioSig's Pure EP System is intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing EP procedures. BioSig says its ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias such as atrial fibrillation and ventricular tachycardia.